COMMUNIQUÉS West-GlobeNewswire

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
26/06/2026
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
26/06/2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings [...]
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
26/06/2026
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal [...]
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
26/06/2026
FDA decision expected by August 2, 2026 WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic [...]
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
26/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its [...]
LIXTE Joins Russell Microcap Index
26/06/2026
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap ® Index, effective after the close [...]
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
26/06/2026
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
26/06/2026
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor [...]
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
26/06/2026
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
26/06/2026
BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc ., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases, today announced that it has [...]
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
26/06/2026
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
26/06/2026
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the [...]
Fortrea Names Jason Knoblauch as Chief Financial Officer
26/06/2026
Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization ( [...]
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
26/06/2026
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE [...]
Complex Small Molecules Are Changing Drug R&D
26/06/2026
Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply. Targeted protein degraders, covalent agents, and a new wave of kinase [...]
Transcom Leading Voices Connects CX Executives Through Peer Learning
26/06/2026
Transcom opens Leading Voices, a platform of real-world advice from leaders working through AI adoption in customer experience. It pairs peer perspectives and learning tools with Transcom's own proven CX results, from [...]
New Autism Research to be Presented at European Purine Scientific Meeting
26/06/2026
CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
26/06/2026
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31 st to [...]
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
26/06/2026
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]

Pages